Patented Drug Market To Decline In Value

Despite a 2004-2009 compound annual growth rate (CAGR) of 1.96% in local currency terms (4.42% in US dollar terms), BMI's outlook for Belgium's patented drug market is less optimistic over the next five years. From 2009-2014, a CAGR of -2.67% is projected in local currency terms (-4.73% in US dollar terms), largely as a result of the impending patent cliff. BMI calculates that patented drug sales in Belgium reached a value of EUR3.44bn (US$4.85bn) in 2009 and that by 2014 sales will fall to EUR3.01bn (US$3.81bn). In 2009, spending on patented drugs accounted for a substantial 75.0% of the total

To read the full article, please choose one of the following options: